I'm LongbridgeAI, I can summarize articles.CASI Pharmaceuticals settled arbitration with Acrotech Biopharma regarding Evomela commercialization rights in China. The agreement rescinds Acrotech's prior termination of the 2014 license, reinstating it with revised minimum purchase obligations. Both parties will seek dismissal of the arbitration with prejudice.
- CASI Pharmaceuticals reached a settlement with Acrotech Biopharma to resolve an arbitration tied to Evomela commercialization rights in China. * The deal rescinds Acrotech’s prior purported termination of the 2014 license agreement, reinstating it subject to revisions. * Revisions include minimum Evomela unit purchase obligations for certain years. * The parties will seek dismissal of the arbitration with prejudice. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-078452), on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here